Diligence memo · auto-generated · as of July 2, 2026
Accufy Diagnostics, Inc.
Accufy Diagnostics, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Accufy Diagnostics, Inc. operates in Biotechnology, based in ROCKVILLE.
Sub-sector tags: medical-devices.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Accufy Diagnostics, Inc. has raised $200K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $200K on 2025-09-23.
Most recent recorded round closed around 2025-09-23.
Valuation (modeled)modeled
Provath models Accufy Diagnostics, Inc. at approximately $431K (range $107K–$998K). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.45× the median modeled value of Pre-Seed Biotechnology companies in 2025–2027 (79 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 9 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 4% of Biotechnology peers (4293 compared).
Modeled value ranks above 1% of those peers.
Closest niche peers: Illexcor Holdings, LLC, Reprogram Biosciences, Inc., Maxymune Therapeutics, Inc., EnZeta Immunotherapies, Inc., Eliaz Therapeutics Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.